---
title: "ITM to Present at Oppenheimer’s 35th Annual Healthcare Life Sciences Conference"
date: "2025-02-07 21:00:01"
summary: "Garching / Munich, February 7, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced its participation in Oppenheimer’s 35th Annual Healthcare Life Sciences Conference. Dr. Andrew Cavey, CEO of ITM, will deliver a virtual corporate presentation highlighting the Company's deep and robust radiopharmaceutical pipeline,..."
categories:
  - "Reuters"
lang:
  - "en"
translations:
  - "en"
tags:
  - "Reuters"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

**Garching / Munich, February 7, 2025 –**ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced its participation in Oppenheimer’s 35th Annual Healthcare Life Sciences Conference. Dr. Andrew Cavey, CEO of ITM, will deliver a virtual corporate presentation highlighting the Company's deep and robust radiopharmaceutical pipeline, opportunities, and upcoming milestones on Tuesday, February 11, 2025 at 8:40 AM ET.

For further information, please contact:

**Investor Relations**

Ben Orzelek

Phone: +49 89 329 8986 1009

Email: investors@itm-radiopharma.com

**Media Contact**

Corporate Communications

Kathleen Noonan/Julia Westermeir

Phone: +49 89 329 8986 1500

Email: communications@itm-radiopharma.com

**About ITM Isotope Technologies Munich SE**

ITM, a leading radiopharmaceutical biotech company, is dedicated to providing a new generation of radiopharmaceutical therapeutics and diagnostics for hard-to-treat tumors. We aim to meet the needs of cancer patients, clinicians and our partners through excellence in development, production and global supply. With improved patient benefit as the driving principle for all we do, ITM advances a broad precision oncology pipeline, including multiple Phase 3 studies, combining the company’s high-quality radioisotopes with a range of targeting molecules. By leveraging our two decades of pioneering radiopharma expertise, central industry position and established global network, ITM strives to provide patients with more effective targeted treatment to improve clinical outcome and quality of life. www.itm-radiopharma.com

**Attachment**

* 20250207\_ITM to Present in Oppenheimers 35th Annual Healthcare Life Sciences Conference

[Reuters](https://www.tradingview.com/news/reuters.com,2025-02-07:newsml_GNX9wN6MR:0-itm-to-present-at-oppenheimer-s-35th-annual-healthcare-life-sciences-conference/)
